Abstract
The discovery and preclinical development of selective dopamine reuptake inhibitors as potential pharmacotherapies for treating cocaine addiction are presented. The studies are based on the hypothesis that a dopamine reuptake inhibitor is expected to partially substitute for cocaine, thus decreasing cocaine self-administration and minimizing the craving for cocaine. This type of indirect agonist therapy has been highly effective for treating smoking addiction (nicotine replacement therapy) and heroin addiction (methadone). To be an effective pharmacotherapy for cocaine addiction, the potential drug must be safe, long-acting, and have minimal abuse potential. We have developed several 3-phenyltropane analogs that are potent dopamine uptake inhibitors, and some are selective for the dopamine transporter relative to the serotonin and norepinephrine transporters. In animal studies, these compounds substitute for cocaine, reduce the intake of cocaine in rats and rhesus monkeys trained to self-administer cocaine, and have demonstrated a slow onset and long duration of action and lack of sensitization. The 3-phenyltropane analogs were also tested in a rhesus monkey self-administration model to define their abuse potential relative to cocaine. Based on these studies, 3β-(4-chlorophenyl)-2β-[3-(4'-methylphenyl)isoxazol-5-yl]tropane (RTI-336) has been selected for preclinical development.
Keywords: RTI-336, dopamine transporter, cocaine abuse, pharmacotherapy, 3-aryltropanes
Full Text
The Full Text of this article is available as a PDF (238.0 KB).
References
- 1.Substance Abuse and Mental Health Services Administration . 200 National Survey on Drug Use and Health. Washington, DC: Department of Health and Human Services; 2003. [Google Scholar]
- 2.Substance Abuse and Mental Health Services Administration . Drug Abuse Warning Network (DAWN) Publications (1994–2002) Washington, DC: Department of Health and Human Services; 2004. [Google Scholar]
- 3.Carroll FI, Howell LL, Kuhar MJ. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem. 1999;42:2721–2736. doi: 10.1021/jm9706729. [DOI] [PubMed] [Google Scholar]
- 4.Howell LL, Wilcox KM. The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. J Pharmacol Exp Ther. 2001;298:1–6. [PubMed] [Google Scholar]
- 5.Newman AH, Kulkarni S. Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic: a focus on analogues of benztropine and rimcazole. Med Res Rev. 2002;22:429–464. doi: 10.1002/med.10014. [DOI] [PubMed] [Google Scholar]
- 6.Carrera MR, Meijler MM, Janda KD. Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem. 2004;12:5019–5030. doi: 10.1016/j.bmc.2004.06.018. [DOI] [PubMed] [Google Scholar]
- 7.Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237:1219–1223. doi: 10.1126/science.2820058. [DOI] [PubMed] [Google Scholar]
- 8.Bergman J, Madras BK, Johnson SE, Spealman RD. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther. 1989;251:150–155. [PubMed] [Google Scholar]
- 9.Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 1991;14:299–302. doi: 10.1016/0166-2236(91)90141-G. [DOI] [PubMed] [Google Scholar]
- 10.Wise RA, Newton P, Leeb K, Burnette B, Pocock D, Justice JB. Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats. Psychopharmacology (Berl) 1995;120:10–20. doi: 10.1007/BF02246140. [DOI] [PubMed] [Google Scholar]
- 11.Wilcox KM, Rowlett JK, Paul IA, Ordway GA, Woolverton WL. On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys: practical and theoretical concerns. Psychopharmacology (Berl) 2000;153:139–147. doi: 10.1007/s002130000457. [DOI] [PubMed] [Google Scholar]
- 12.Carroll FI. 2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy. J Med Chem. 2003;46:1775–1794. doi: 10.1021/jm030092d. [DOI] [PubMed] [Google Scholar]
- 13.Carroll FI, Runyon SP, Abraham P, et al. Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers. J Med Chem. 2004;47:6401–6409. doi: 10.1021/jm0401311. [DOI] [PubMed] [Google Scholar]
- 14.Balster RL, Carroll FI, Graham JH, et al. Potent substituted-3b-phenyltropane analogs of cocaine have cocaine-like discriminative stimulus effects. Drug Alcohol Depend. 1991;29:145–151. doi: 10.1016/0376-8716(91)90043-X. [DOI] [PubMed] [Google Scholar]
- 15.Fleckenstein AE, Kopajtic TA, Boja JW, Carroll FI, Kuhar MJ. Highly potent cocaine analogs cause long-lasting increases in locomotor activity. Eur J Pharmacol. 1996;311:109–114. doi: 10.1016/0014-2999(96)00423-2. [DOI] [PubMed] [Google Scholar]
- 16.Fowler JS, Volkow ND, Logan J, et al. Measuring dopamine transporter occupancy by cocaine in vivo: radiotracer considerations. Synapse. 1998;28:111–116. doi: 10.1002/(SICI)1098-2396(199802)28:2<111::AID-SYN1>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
- 17.Volkow ND, Wang GJ, Fischman MW, et al. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci. 2000;67:1507–1515. doi: 10.1016/S0024-3205(00)00731-1. [DOI] [PubMed] [Google Scholar]
- 18.Zernig G, Giacomuzzi S, Riemer Y, Wakonigg G, Sturm K, Saria A. Intravenous drug injection habits: drug user's self-reports versus researchers' perception. Pharmacology. 2003;68:49–56. doi: 10.1159/000068731. [DOI] [PubMed] [Google Scholar]
- 19.Balster RL, Schuster CR. Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav. 1973;20:119–129. doi: 10.1901/jeab.1973.20-119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Woolverton WL, Wang Z. Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol. 2004;486:251–257. doi: 10.1016/j.ejphar.2004.01.003. [DOI] [PubMed] [Google Scholar]
- 21.Lile JA, Morgan D, Birmingham AM, et al. The reinforcing efficacy of the dopamine reuptake inhibitor 2beta-propanoyl-3beta-(4-tolyl)-tropane (PTT) as measured by a progressive-ratio schedule and a choice procedure in rhesus monkeys. J Pharmacol Exp Ther. 2002;303:640–648. doi: 10.1124/jpet.102.039180. [DOI] [PubMed] [Google Scholar]
- 22.Woolverton WL, Ranaldi R, Wang Z, et al. Reinforcing strength of a novel dopamine transporter ligand: pharmacodynamic and pharmacokinetic mechanisms. J Pharmacol Exp Ther. 2002;303:211–217. doi: 10.1124/jpet.102.037812. [DOI] [PubMed] [Google Scholar]
- 23.Samaha AN, Robinson TE. Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci. 2005;26:82–87. doi: 10.1016/j.tips.2004.12.007. [DOI] [PubMed] [Google Scholar]
- 24.Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9:557–569. doi: 10.1038/sj.mp.4001507. [DOI] [PubMed] [Google Scholar]
- 25.Carroll FI, Pawlush N, Kuhar MJ, Pollard GT, Howard JL. Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3beta-(substituted phenyl)-2beta-(3'-substituted isoxazol-5-yl)tropanes. J Med Chem. 2004;47:296–302. doi: 10.1021/jm030453p. [DOI] [PubMed] [Google Scholar]
- 26.Lindsey KP, Wilcox KM, Votaw JR, et al. Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging. J Pharmacol Exp Ther. 2004;309:959–969. doi: 10.1124/jpet.103.060293. [DOI] [PubMed] [Google Scholar]